The OncoAlert🚨ROUND UP  Now Out‼️ Covering May 15-22, 2025  REGISTER at

Join our Urology colleagues, Dr. Melao and Dr. Spiess, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. They’ll also explore long-term renal ...

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025.

Discussing:Association between risk-reducing surgeries and survival in young BRCA carriers with #BreastCancer DESTINY-Breast11 Update from Industry

This international retrospective cohort study evaluated the safety of assisted reproductive technology (ART) in BRCA1/2 carriers who conceived after a breast cancer diagnosis at age 40 or younger. Among 543 women, 107 conceived using ART and 43...

Join Dr. Jemal & Dr Morgan as they discuss this report, a collaboration among major U.S. cancer surveillance organizations, presents the latest national data on cancer incidence and mortality. Using data from cancer registries ...

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities....

The OncoAlertWeekly Round Up   Covering the TOP of the week April 18-24, 2025  REGISTER at http://OncoAlert360.com OR https://oncoalert.m-...

Study compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE and NATALEE trials among patients with hormone receptor-positive/HER2-negative early

Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lun...

Dear Colleagues,Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:Prognostic implications of risk definitions from the monarchE and NATALEE trial

Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology. The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standar...

The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therap...

Oncology Here & NowIn this interview, OncoAlert faculty members Dr. Joseph McCollom from Parkview Health (USA) and Dr. Cristiane Bergerot from OncoClinicas (Brazil) explore supportive care and the future of telemedicine. Their discus...

Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse l...